New Releases from NCBI BookshelfLutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments.​Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments.

Post Content

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top